These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35679695)

  • 1. "COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada.
    Glegg S; McCrae K; Kolla G; Touesnard N; Turnbull J; Brothers TD; Brar R; Sutherland C; Le Foll B; Sereda A; Goyer MÈ; Rai N; Bernstein S; Fairbairn N
    Int J Drug Policy; 2022 Aug; 106():103742. PubMed ID: 35679695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
    Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
    Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
    Jaffe K; Blawatt S; Lehal E; Lock K; Easterbrook A; MacDonald S; Harrison S; Lajeunesse J; Byres D; Schechter M; Oviedo-Joekes E
    Harm Reduct J; 2023 Apr; 20(1):51. PubMed ID: 37060027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community partner perspectives on the implementation of a novel safer supply program in Canada: a qualitative study of the MySafe Project.
    Mansoor M; Foreman-Mackey A; Ivsins A; Bardwell G
    Harm Reduct J; 2023 Apr; 20(1):61. PubMed ID: 37118799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19.
    McCrae K; Glegg S; Goyer MÉ; Le Foll B; Brar R; Sutherland C; Fairbairn N
    Harm Reduct J; 2022 Jul; 19(1):77. PubMed ID: 35836189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribed safer supply during dual public health emergencies: a qualitative study examining service providers perspectives on early implementation.
    McCall J; Hobbs H; Ranger C; Cameron F; Stuart H; Nelken J; Majalahti J; Urbanoski K; Kolla G; LeMaistre J; Toombs K; Herriot R; Pauly B
    Subst Abuse Treat Prev Policy; 2024 Mar; 19(1):19. PubMed ID: 38444035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.
    Kolla G; Pauly B; Cameron F; Hobbs H; Ranger C; McCall J; Majalahti J; Toombs K; LeMaistre J; Selfridge M; Urbanoski K
    Harm Reduct J; 2024 Jun; 21(1):111. PubMed ID: 38849866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study.
    Bardwell G; Bowles JM; Mansoor M; Werb D; Kerr T
    Subst Abuse Treat Prev Policy; 2023 Mar; 18(1):14. PubMed ID: 36869358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
    Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
    CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies.
    Giang K; Charlesworth R; Thulien M; Mulholland A; Barker B; Brar R; Pauly B; Fast D
    Int J Drug Policy; 2023 May; 115():104023. PubMed ID: 37059025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supervised Tablet Injectable Opioid Agonist Therapy (TiOAT): A Strategy to Address Safer Supply for Individuals With an Opioid Use Disorder?
    Weng J; Fairbairn N; Sutherland C; Johnson C; Nolan S
    J Addict Med; 2022 May-Jun 01; 16(3):258-260. PubMed ID: 34145188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada.
    Foreman-Mackey A; Pauly B; Ivsins A; Urbanoski K; Mansoor M; Bardwell G
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):66. PubMed ID: 36209227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safer opioid supply: qualitative program evaluation.
    Haines M; O'Byrne P
    Harm Reduct J; 2023 Apr; 20(1):53. PubMed ID: 37081500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable opioid agonist treatment: An evolutionary concept analysis.
    Haines M; O'Byrne P
    Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.
    Young S; Kolla G; McCormack D; Campbell T; Leece P; Strike C; Srivastava A; Antoniou T; Bayoumi AM; Gomes T
    Int J Drug Policy; 2022 Apr; 102():103601. PubMed ID: 35124413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping a moral panic: News media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada.
    Michaud L; Kolla G; Rudzinski K; Guta A
    Int J Drug Policy; 2024 May; 127():104423. PubMed ID: 38642543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis.
    Karamouzian M; Rafat B; Kolla G; Urbanoski K; Atkinson K; Bardwell G; Bonn M; Touesnard N; Henderson N; Bowles J; Boyd J; Brunelle C; Eeuwes J; Fikowski J; Gomes T; Guta A; Hyshka E; Ivsins A; Kennedy MC; Laurence G; Martignetti L; Nafeh F; Salters K; Tu D; Strike C; Pauly B; Werb D
    Int J Drug Policy; 2023 Oct; 120():104157. PubMed ID: 37574645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How an emergency department is organized to provide opioid-specific harm reduction and facilitators and barriers to harm reduction implementation: a systems perspective.
    Jiao S; Bungay V; Jenkins E; Gagnon M
    Harm Reduct J; 2023 Sep; 20(1):139. PubMed ID: 37735432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights from Drug Checking Programs: Practicing Bootstrap Public Health Whilst Tailoring to Local Drug User Needs.
    Ondocsin J; Ciccarone D; Moran L; Outram S; Werb D; Thomas L; Arnold EA
    Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.